2026-04-29T07:22:54Zhttps://repisalud.isciii.es/rest/oai/request
oai:repisalud.isciii.es:20.500.12105/185012024-11-28T15:23:55Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16927
Repisalud author Villanueva-Paz, Marina author Niu, Hao author Segovia-Zafra, Antonio author Medina-Caliz, Inmaculada author Sanabria-Cabrera, Judith author Lucena, M. Isabel author Andrade, Raúl J. author Alvarez-Alvarez, Ismael authoraffiliation [Villanueva-Paz,M; Niu,H; Segovia-Zafra,A; Medina-Caliz,I; Sanabria-Cabrera,J; Lucena,MI; Andrade,RJ; Alvarez-Alvarez,I] Unidad de Gestión Clínica de Gastroenterología, Servicio de Farmacología Clínica, Instituto de Investigación Biomédica de Málaga-IBIMA, Hospital Universitario Virgen de la Victoria, Universidad de Málaga. [Niu,H; Segovia-Zafra,A; Sanabria-Cabrera,J; Lucena,MI; Andrade,RJ; Alvarez-Alvarez,I] Centro de Investigación Biomédica en Red en el Área Temática de Enfermedades Hepáticas y Digestivas (CIBERehd), Madrid, Spain. [Sanabria-Cabrera,J; Lucena,MI] Plataforma ISCIII de Ensayos Clinicos, UICEC-IBIMA, Malaga, Spain. 2024-02-19T15:31:59Z 2024-02-19T15:31:59Z 2021-11-15 http://hdl.handle.net/10668/3535 http://hdl.handle.net/20.500.12105/18501 34830594 10.3390/jcm10225317 2077-0383 Journal of Clinical Medicine Drug-induced liver injury (DILI) encompasses the unexpected damage that drugs can cause to the liver. DILI may develop in the context of an immunoallergic syndrome with cutaneous manifestations, which are sometimes severe (SCARs). Nevirapine, allopurinol, anti-epileptics, sulfonamides, and antibiotics are the most frequent culprit drugs for DILI associated with SCARs. Interestingly, alleles HLA-B*58:01 and HLA-A*31:01 are associated with both adverse reactions. However, there is no consensus about the criteria used for the characterization of liver injury in this context, and the different thresholds for DILI definition make it difficult to gain insight into this complex disorder. Moreover, current limitations when evaluating causality in patients with DILI associated with SCARs are related to the plethora of causality assessment methods and the lack of consensual complementary tools. Finally, the management of this condition encompasses the treatment of liver and skin injury. Although the use of immunomodulant agents is accepted for SCARs, their role in treating liver injury remains controversial. Further randomized clinical trials are needed to test their efficacy and safety to address this complex entity. Therefore, this review aims to identify the current gaps in the definition, diagnosis, prognosis, and management of DILI associated with SCARs, proposing different strategies to fill in these gaps. eng Drug-induced liver injury Severe cutaneous adverse reactions Hypersensitivity Gaps Causality assessment Diagnosis Management Clinical trial Immune response Enfermedad hepática inducida por sustancias y drogas Hipersensibilidad Relaciones intergeneracionales Diagnóstico Ensayo clínico Inmunidad Critical Review of Gaps in the Diagnosis and Management of Drug-Induced Liver Injury Associated with Severe Cutaneous Adverse Reactions review article